BIOSIRIUS sits at the intersection of intensive‑care medicine and translational immunology — developing programmes for patients with the most severe forms of acute disease. Our current work is anchored in the biology of interleukin‑18.
BIOSIRIUS is building a portfolio of programmes in severe illness. The lead programme — and the focus of our current research — is built on the biology of interleukin-18 (IL-18), a central regulator of the cytokine response that, when uncontrolled, drives many of the worst clinical outcomes in critical care.
IL-18 is the end-product of inflammasome activation across multiple cell types. In severe disease, normal negative-feedback control by IL-18 binding protein (IL-18bp) can fail, leaving the biologically active “free” fraction elevated.
Loss of IL-18 negative feedback is implicated in macrophage activation syndrome and overlaps mechanistically with the dysregulated immune states observed in severe pneumonia and ARDS.
Our published 206-patient hospital cohort showed that elevated free IL-18 from symptom day 15 onwards was associated with severity and mortality — providing an evidence base for driving new treatments in this underserved condition.
BIOSIRIUS’s strength is the people behind it — practising intensive‑care physicians, immunologists, and trial‑design advisors who have already taken a clinical question through study design, data, and peer review. The patent landscape around our current work is one outcome of that, not the focus.
The team’s daily working environment is the intensive care unit, the immunology lab, and the hospital corridors where decisions about severely unwell patients are actually made. That clinical grounding shapes every decision we take about future development.
First-hand experience of intensive care, severe respiratory failure, and the multi-organ dysfunction that defines the patients most likely to benefit from new approaches.
Disciplined thinking about which patients, at which point in their illness, and on which biomarkers — the practical questions that determine whether a programme is realistic.
Bridging mechanism, biomarker, and clinical endpoint into a development logic that a regulator, a sponsor, and a critical-care physician can all recognise.
Pragmatic thinking about study populations, stratification, and endpoints — informed by clinical-trial design experience within the team and its advisors.
A measured path: scientific question → clinical dataset → peer-reviewed evidence → granted IP → expanding translational programme. Each step before it was secured.
Hypothesis-driven study of IL-18 negative-feedback failure in severe respiratory illness, designed and registered prospectively from intensive-care experience.
Prospective collection and analysis of a 206-patient hospital cohort, with longitudinal cytokine measurement and outcome data.
Findings published in Intensive Care Medicine Experimental, providing the underlying clinical evidence base.
Intellectual property covering the team’s current lead area was formally granted — one outcome of the preceding clinical and laboratory work.
Additional research lines and IP development in critical illness and inflammatory disease, building on the underlying science.
Selective partnerships with scientific, clinical, and strategic counterparties to advance development-ready programmes — at our own pace, with the right collaborators.
BIOSIRIUS brings together people who have spent careers at the bedside of severely unwell patients, in clinical immunology laboratories, and in the regulatory and trial-design environments where translational programmes are actually built.
ICU physician and translational researcher. Designed and led the prospective cohort study underpinning BIOSIRIUS’s scientific basis, published in 2023 in Intensive Care Medicine Experimental. Drives the company’s scientific direction and translational strategy.
Consultant physician in allergy and clinical immunology at Cambridge University Hospitals, and an associate professor with long-standing experience advising regulatory and industry bodies on therapeutic decisions in severe disease. Brings clinical, regulatory, and senior medical leadership experience to BIOSIRIUS.
Director of the Cambridge Cytokine and Cellular Immunity laboratory at Cambridge University Hospitals; extensively published immunologist, with deep expertise in cytokine measurement and inflammatory disease biology.
Consultant in intensive care and respiratory medicine, with published clinical-trial experience in severe respiratory illness. Advises on study design, patient selection, and pragmatic endpoints.
Former biotech CFO with extensive public-equities and capital-markets experience in life sciences. Advises BIOSIRIUS on financing, governance, and corporate strategy.
Senior life-sciences operator with deep experience in pharmaceutical supply chain and operational scale-up across regulated medical environments.
We welcome serious conversations with strategic partners, investors, scientific collaborators, and prospective advisors. Direct, written introductions are the most effective route.
Please note that confidential and commercially sensitive material is shared only under appropriate written agreements with serious counterparties.
